Mycophenolate mofetil

  title={Mycophenolate mofetil},
  author={JamesJ. Lipsky},
  journal={The Lancet},

Topics from this paper

Variability in the pharmacokinetics of mycophenolic acid: Implications for therapeutic drug monitoring
The aim of this thesis was to further explain the differences in the pharmacokinetics of MMF seen between renal transplant recipients, investigate the validity of these results in other populations, or when different formulations are used, and to describe the effects ofThese results on individualization of the MMF treatment. Expand
The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum.
REPORT OF A CASE A 32-year-old white woman with systemic lupus erythematosus presented with a 2-year history of refractory pyoderma gangrenosum on the left pretibial area. The lesion eroded to exposeExpand
Host-Immune Interactions in JC Virus Reactivation and Development of Progressive Multifocal Leukoencephalopathy (PML)
The current literature on host factor- mediated and immune factor-mediated regulation of JCV gene expression is discussed with the purpose of developing a model of the factors that are bypassed during JCV reactivation, and thus are potential targets for the development of therapeutic interventions to suppress PML initiation. Expand
Pharmacokinetic evaluation of mycophenolate mofetil for pemphigus
Mycophenolate mofetil (MMF), originally developed for preventing allograft rejection, appears to be effective in autoimmune blistering diseases in combination with systemic corticosteroid or as a monotherapy, and demonstrates complex pharmacokinetics and displays large between-subject pharmacokinetic variability. Expand
CD69 expression on peripheral CD4+ T cells parallels disease activity and is reduced by mycophenolate mofetil therapy in uveitis.
Reduction in uveitis activity during MMF therapy correlates with reduction in frequency of peripheral blood CD69-positive CD4 cells, which is a measure of activity in posterior Uveitis and may guide adequate immunosuppression. Expand
Limited Sampling Strategy for Estimation of Mycophenolic Acid Exposure in Adult Chinese Heart Transplant Recipients
The results provide strong evidence for the use of LSS model other than a single time-point concentration of MPA when performing TDM, and both internal and external validations showed good applicability for four-point LSS equation. Expand
Discovery of lixisenatide analogues as long-acting hypoglycemic agents using novel peptide half-life extension technology based on mycophenolic acid
Noncovalent binding of peptides to human serum albumin protects against renal clearance and enzymatic degradation. Herein, we investigated the effect of mycophenolic acid (MPA) albumin binders forExpand
E.U. paediatric MOG consortium consensus: Part 5 - Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
  • A. Bruijstens, E. Wendel, +18 authors R. Neuteboom
  • Medicine
  • European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
  • 2020
Four first-line therapies consisting of rituximab (RTX), azathioprine, mycophenolate mofetil or monthly IVIG have been identified and the consensus group recommends treatment escalation with RTX or IVIG, followed by combining those two, and ultimately adding maintenance oral steroids. Expand
Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology
A broad array of trials with mycophenolate mofetil, azathioprine and/or tacrolimus are ongoing within the field of rheumatology that might provide further novel avenues for the use of these drugs. Expand